tradingkey.logo
tradingkey.logo
Search

Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

ReutersJun 4, 2025 11:13 AM
facebooktwitterlinkedin

- Vigil Neuroscience Inc VIGL.O:

  • VIGIL NEUROSCIENCE PROVIDES UPDATE ON ILUZANEBART PHASE 2 IGNITE TRIAL IN ALSP

  • VIGIL NEUROSCIENCE INC - ILUZANEBART SHOWS FAVORABLE SAFETY AND TOLERABILITY PROFILE

  • VIGIL NEUROSCIENCE INC - PHASE 2 LONG-TERM EXTENSION STUDY DISCONTINUED

  • VIGIL NEUROSCIENCE INC - PHASE 2 IGNITE TRIAL SHOWS NO BENEFICIAL EFFECTS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI